JPMorgan analyst Cory Kasimov called the data "Roc solid," while SVB Leerink's Joseph Schwartz said the treatment's durability is "respectable."The other companies whose drugs the agency said they will make rule on are:     Disclosure: The author has positions in Pfizer, Bristol-Myers Squibb, Gilead Sciences and Eli Lilly.